​The mutual recognition agreement between Israel and the EU on drugs was ratified today with a large majority in favor in the European Parliament.
The agreement serves as recognition by the EU of the quality of the drug manufacturing in Israel and of the quality of the supervision by the institute for auditing and standards of medical products within the Ministry of Health – of the GMP of drug manufacturers and importers in Israel.

The agreement will improve accessibility of Israeli manufactured drugs to  and from the European market.
Implementation of the agreement will exempt Israeli manufacturers exporting to Europe from the requirement to perform laboratory tests on every shipment from Israel to Europe.
Furthermore, the results of audits being performed by the institute for auditing and standards of medical products within the Ministry of Health will be recognized by the European countries, thus obviating the audits performed in Israeli drug manufacturing plants by the authorities in the European countries.